KITLG and psoriasis: In agreement with our study, psoriatic skin-treated with ScF had a significantly low levels of mTOR protein alongside the downregulation of TNF-α, IL-1β, and IL-17 (Fig. 3) indicating an inhibitory effect of ScF on mTOR signaling (Fig. 5) to mitigate psoriasis severity.